Sorted By Test Name - Mayo Medical Laboratories

GDUR
89316
myocardium have also been observed, often with fatal results. Three hemodialysis treatments are required
to substantially remove gadolinium from patients with impaired renal function; peritoneal dialysis is not
effective.
Useful For: This test is useful for evaluation of dermal tissue. No other tissue types have been
validated. The reference range applies only to dermal tissue. Diagnosis of nephrogenic systemic fibrosis
by documenting gadolinium deposition in affected dermal tissue.
Interpretation: Elevated gadolinium (>0.5 mcg/g) observed in dermal tissue specimens collected more
than 48 hours after administration of gadolinium-containing contrast media indicates gadolinium
deposition. These patients have increased risk of nephrogenic systemic fibrosis (NSF). In individuals with
NSF, affected tissues are likely to contain gadolinium at concentrations in the range of 4 to 186 mcg/g.
Unaffected tissues from gadolinium-exposed subjects exhibit gadolinium concentration of 0.6 mcg/g to 28
mcg/g. A reportable gadolinium concentration in tissue suggests recent administration of
gadolinium-containing contrast media. In association with reduced renal function, these findings indicate
a risk of NSF.
Reference Values:
0.5 mcg/L) observed in a random urine specimen collected >48
hours after administration of gadolinium-containing contrast media indicates impaired ability to eliminate
gadolinium. These patients have an increased risk of developing nephrogenic systemic fibrosis. A normal
value is